After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?

 
• By Brenda Sandburg
  
Xtandi march in
NIH rejects petition seeking march-in rights to prostate cancer drug patents • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access